The Beauty Health Company(SKIN)Earnings, Financials & Key Ratios

SKIN•NASDAQ

$0.90

$116M mkt cap·Price updated May 6, 2026

SectorConsumer Defensive IndustryHousehold Products Sub-IndustrySuppliers, Durables and Specialty Retailers

AboutThe Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.Show more

Revenue$301M-10.0%
EBITDA$36K+100.1%
Net Income-$10M+67.4%
EPS (Diluted)-0.16+55.6%
Gross Margin65.29%+19.7%
EBITDA Margin0.01%+100.1%
Operating Margin-6.91%+65.9%
Net Margin-3.16%+63.7%
ROE-16.83%+67.8%
ROIC-6.83%+63.8%
Debt/Equity6.20-43.5%
Interest Coverage-1.08+41.4%

Technical→

SKIN Key Insights

The Beauty Health Company (SKIN) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

✓Strong 5Y profit CAGR of 20.1%
✓Strong Piotroski F-Score: 7/9
✓Strong 5Y sales CAGR of 20.4%
✓Share count reduced 4.7% through buybacks

✗Weaknesses

✗High debt to equity ratio of 6.2x
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

SKIN Price & Volume

The Beauty Health Company (SKIN) stock price & volume — 10-year historical chart

Loading chart...

SKIN Growth Metrics

The Beauty Health Company (SKIN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years20.36%

3 Years-6.32%

TTM-10.01%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM67.3%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM52.22%

Return on Capital

10 Years-5.62%

5 Years-7.48%

3 Years-9.65%

Last Year-4.47%

SKIN Recent Earnings

The Beauty Health Company (SKIN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)

Q2 2026Latest

Mar 12, 2026

EPS

$0.06

Est $0.07

+14.3%

Revenue

$82M

Est $78M

+5.4%

Q4 2025

Nov 6, 2025

EPS

$0.09

Est $0.08

-12.5%

Revenue

$71M

Est $78M

-9.5%

Q3 2025

Aug 7, 2025

EPS

$0.03

Est $0.06

+150.0%

Revenue

$78M

Est $68M

+14.4%

Q2 2025

May 8, 2025

EPS

$0.08

Est $0.13

+38.5%

Revenue

$70M

Est $63M

+10.3%

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Mar 12, 2026	$0.06vs $0.07+14.3%	$82Mvs $78M+5.4%
Q4 2025	Nov 6, 2025	$0.09vs $0.08-12.5%	$71Mvs $78M-9.5%
Q3 2025	Aug 7, 2025	$0.03vs $0.06+150.0%	$78Mvs $68M+14.4%
Q2 2025	May 8, 2025	$0.08vs $0.13+38.5%	$70Mvs $63M+10.3%

Based on last 12 quarters of dataView full earnings history →

Company	Market Cap	Stock Price	P/E Ratio (TTM)	Revenue Growth 1Y	Net Margin	Return on Equity (ROE)	FCF Yield	Debt / Equity
ELFe.l.f. Beauty, Inc.Direct Competitor	3.31B	59.42	30.95	28.28%	6.84%	8.95%	3.48%	0.41
IPARInter Parfums, Inc.Direct Competitor	2.94B	91.70	17.50	2.49%	13.46%	18.37%	6.48%	0.20
COTYCoty Inc.Direct Competitor	2.25B	2.56	-5.82	-3.68%	-9.26%	-14.21%	12.32%	1.07
NUSNu Skin Enterprises, Inc.Direct Competitor	353.31M	7.33	2.31	-14.26%	7.02%	13.7%	13.02%	0.35
USNAUSANA Health Sciences, Inc.Direct Competitor	355.48M	19.26	33.21	8.28%	1.16%	1.84%	2.4%	0.02
ESTAEstablishment Labs Holdings Inc.Direct Competitor	2.06B	70.99	-41.27	27.14%	-24.19%	-216.86%		0.12
INMDInMode Ltd.Product Competitor	912.37M	14.40	10.07	-6.16%	25.33%	13.73%	9.24%	0.02
SSKNSTRATA Skin Sciences, Inc.Product Competitor	5.74M	0.15	-0.58	0.61%	-35.64%	-8.4%		3.31

Compare SKIN vs Peers

The Beauty Health Company (SKIN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ELF

Most directly comparable listed peer for SKIN.

Scale Benchmark

vs AMZN

Larger-name benchmark to compare SKIN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ELF, IPAR, COTY, NUS

SKIN Income Statement

The Beauty Health Company (SKIN) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily

Line item	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Sales/Revenue	166.62M	119.09M	260.09M	365.88M	397.99M	334.29M	300.8M
Revenue Growth %	-	-28.53%	118.39%	40.67%	8.78%	-16%	-10.02%
Cost of Goods Sold	60.11M	51.89M	81.55M	117.1M	242.88M	152M	104.4M
COGS % of Revenue	36.08%	43.57%	31.35%	32%	61.03%	45.47%	34.71%
Gross Profit	106.51M▲ 0%	67.2M▼ 36.9%	178.54M▲ 165.7%	248.78M▲ 39.3%	155.11M▼ 37.7%	182.3M▲ 17.5%	196.4M▲ 7.7%
Gross Margin %	63.92%	56.43%	68.65%	68%	38.97%	54.53%	65.29%
Gross Profit Growth %	-	-36.91%	165.69%	39.34%	-37.65%	17.52%	7.74%
Operating Expenses	93.05M	84.38M	218.47M	274.62M	286.03M	250.07M	217.1M
OpEx % of Revenue	55.84%	70.85%	84%	75.06%	71.87%	74.81%	72.17%
Selling, General & Admin	88.44M	80.97M	210.27M	266.18M	275.93M	243.77M	211.5M
SG&A % of Revenue	53.08%	67.99%	80.85%	72.75%	69.33%	72.92%	70.31%
Research & Development	4.61M	3.41M	8.2M	8.44M	10.1M	6.3M	5.6M
R&D % of Revenue	2.77%	2.86%	3.15%	2.31%	2.54%	1.88%	1.86%
Other Operating Expenses	0	0	0	0	0	0	0
Operating Income	13.46M▲ 0%	-17.18M▼ 227.6%	-39.93M▼ 132.4%	-25.84M▲ 35.3%	-130.92M▼ 406.6%	-67.77M▲ 48.2%	-20.8M▲ 69.3%
Operating Margin %	8.08%	-14.43%	-15.35%	-7.06%	-32.89%	-20.27%	-6.91%
Operating Income Growth %	-	-227.63%	-132.38%	35.28%	-406.63%	48.23%	69.31%
EBITDA	27.2M	-2.78M	-22M	-2.97M	-96.24M	-38.3M	36K
EBITDA Margin %	16.32%	-2.34%	-8.46%	-0.81%	-24.18%	-11.46%	0.01%
EBITDA Growth %	-	-110.22%	-691.01%	86.51%	-3142.65%	60.21%	100.09%
D&A (Non-Cash Add-back)	13.74M	14.4M	17.93M	22.87M	34.67M	29.48M	20.84M
EBIT	14.16M	-17.21M	-368.86M	58.73M	-88.24M	-19.14M	-20.8M
Net Interest Income	-17.09M	-21.27M	-11.74M	-4.22M	9.52M	6.23M	-10.37M
Interest Income	0	0	39K	9.18M	23.17M	16.64M	8.95M
Interest Expense	17.09M	21.27M	11.78M	13.39M	13.65M	10.41M	19.3M
Other Income/Expense	-16.4M	-21.3M	-340.71M	71.18M	29.03M	38.22M	14.87M
Pretax Income	-2.94M▲ 0%	-38.48M▼ 1211.2%	-380.64M▼ 889.1%	45.34M▲ 111.9%	-101.89M▼ 324.7%	-29.55M▲ 71.0%	-5.94M▲ 79.9%
Pretax Margin %	-1.76%	-32.31%	-146.35%	12.39%	-25.6%	-8.84%	-1.97%
Income Tax	-1.3M	-9.31M	-1.88M	1.11M	-1.77M	-452K	3.58M
Effective Tax Rate %	44.19%	24.19%	0.49%	2.46%	1.74%	1.53%	-60.31%
Net Income	-1.64M▲ 0%	-29.18M▼ 1681.1%	-378.76M▼ 1198.2%	44.22M▲ 111.7%	-100.12M▼ 326.4%	-29.1M▲ 70.9%	-9.5M▲ 67.4%
Net Margin %	-0.98%	-24.5%	-145.63%	12.09%	-25.16%	-8.7%	-3.16%
Net Income Growth %	-	-1681.14%	-1198.25%	111.68%	-326.38%	70.94%	67.35%
Net Income (Continuing)	-1.64M	-29.18M	-378.76M	44.22M	-100.12M	-29.1M	-9.5M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)	-0.05▲ 0%	-0.85▼ 1566.7%	-3.67▼ 331.8%	-0.23▲ 93.7%	-0.76▼ 230.4%	-0.36▲ 52.6%	-0.16▲ 55.6%
EPS Growth %	-	-1566.67%	-331.76%	93.73%	-230.43%	52.63%	55.56%
EPS (Basic)	-0.05	-0.85	-3.67	0.30	-0.76	-0.23	-0.08
Diluted Shares Outstanding	32.14M	34.29M	102.11M	148.51M	131.68M	142.49M	135.8M
Basic Shares Outstanding	32.14M	34.29M	102.11M	147.55M	131.68M	123.83M	126.38M
Dividend Payout Ratio	-	-	-	-	-	-	-

SKIN Balance Sheet

The Beauty Health Company (SKIN) balance sheet — assets, liabilities & shareholders' equity

Line item	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Total Current Assets	54.17M	59.09M	1B	783.27M	698.25M	477.12M	309.5M
Cash & Short-Term Investments	7.31M	9.49M	901.89M	568.2M	523.02M	370.06M	232.7M
Cash Only	7.31M	9.49M	901.89M	568.2M	523.02M	370.06M	232.7M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	23.72M	23.19M	51.42M	77.77M	55.03M	28.46M	23.44M
Days Sales Outstanding	51.96	71.06	72.17	77.59	50.47	31.08	28.44
Inventory	19.43M	23.2M	35.26M	109.66M	91.32M	69.11M	48M
Days Inventory Outstanding	118.01	163.2	157.82	341.81	137.24	165.96	167.82
Other Current Assets	0	2.58M	0	27.65M	28.88M	9.49M	5.36M
Total Non-Current Assets	172.18M	163.74M	217.91M	219.81M	230.86M	208.56M	190.3M
Property, Plant & Equipment	10.8M	9.19M	31.18M	33.82M	26.35M	19.57M	14.1M
Fixed Asset Turnover	15.43x	12.96x	8.34x	10.82x	15.11x	17.08x	21.33x
Goodwill	98.52M	98.53M	123.69M	124.59M	125.82M	123.5M	126.6M
Intangible Assets	60.29M	50.94M	56.01M	46.39M	62.12M	47.51M	35.8M
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	2.34M	4.81M	6.71M	14.19M	16.04M	14.09M	11.9M
Total Assets	226.35M▲ 0%	222.84M▼ 1.6%	1.22B▲ 447.0%	1B▼ 17.7%	929.11M▼ 7.4%	685.68M▼ 26.2%	499.8M▼ 27.1%
Asset Turnover	0.74x	0.53x	0.21x	0.36x	0.43x	0.49x	0.60x
Asset Growth %	-	-1.55%	446.95%	-17.7%	-7.37%	-26.2%	-27.11%
Total Current Liabilities	37.82M	30.93M	76.44M	71.71M	115.01M	68.15M	186.3M
Accounts Payable	14.26M	18.48M	29.05M	28.47M	44.77M	21.94M	15.6M
Days Payables Outstanding	86.57	130.02	130.02	88.73	67.28	52.69	54.54
Short-Term Debt	8.93M	512K	0	0	0	0	129.09M
Deferred Revenue (Current)	0	0	0	0	450K	2.38M	0
Other Current Liabilities	0	2.46M	18.28M	5.64M	25.01M	2.14M	40.36M
Current Ratio	1.43x	1.91x	13.09x	10.92x	6.07x	7.00x	1.66x
Quick Ratio	0.92x	1.16x	12.63x	9.39x	5.28x	5.99x	1.40x
Cash Conversion Cycle	83.4	104.24	99.97	330.66	120.43	144.35	141.72
Total Non-Current Liabilities	189.74M	221.87M	840.07M	764.32M	754.72M	565.73M	252.47M
Long-Term Debt	180.85M	216.02M	729.91M	734.14M	738.37M	552.2M	240.43M
Capital Lease Obligations	276K	0	12.78M	12.69M	9.32M	10.81M	9.24M
Deferred Tax Liabilities	8.29M	3.99M	3.56M	2.01M	702K	396K	393K
Other Non-Current Liabilities	325K	1.85M	93.82M	15.47M	6.32M	2.32M	2.41M
Total Liabilities	227.56M	252.79M	916.51M	836.03M	869.72M	633.88M	438.7M
Total Debt	190.2M	216.54M	746.41M	751.79M	752.29M	568.16M	378.7M
Net Debt	182.89M	207.05M	-155.48M	183.59M	229.26M	198.09M	146M
Debt / Equity	-	-	2.47x	4.50x	12.67x	10.97x	6.20x
Debt / EBITDA	6.99x	-	-	-	-	-	10519.44x
Net Debt / EBITDA	6.72x	-	-	-	-	-	4055.56x
Interest Coverage	0.83x	-0.81x	-31.32x	4.39x	-6.46x	-1.84x	-1.08x
Total Equity	-1.21M▲ 0%	-29.96M▼ 2380.1%	302.3M▲ 1109.0%	167.05M▼ 44.7%	59.39M▼ 64.4%	51.8M▼ 12.8%	61.1M▲ 17.9%
Equity Growth %	-	-2380.13%	1109%	-44.74%	-64.45%	-12.77%	17.95%
Book Value per Share	-0.04	-0.87	2.96	1.12	0.45	0.36	0.45
Total Shareholders' Equity	-1.21M	-29.96M	302.3M	167.05M	59.39M	51.8M	61.1M
Common Stock	0	4K	16K	14K	12K	12K	13K
Retained Earnings	-14.43M	-43.6M	-418.71M	-378.75M	-478.87M	-507.96M	-517.5M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	28K	242K	-1.26M	-4.53M	-3.04M	-6.95M	-1.4M
Minority Interest	0	0	0	0	0	0	0

SKIN Cash Flow Statement

The Beauty Health Company (SKIN) cash flow — operating, investing & free cash flow history

Line item	Dec'19	Dec'20	Dec'21	Dec'22	Dec'23	Dec'24	Dec'25
Cash from Operations	1.73M	-12.44M	-28.36M	-106.6M	21.75M	16.13M	37.5M
Operating CF Margin %	1.04%	-10.44%	-10.9%	-29.14%	5.46%	4.83%	12.47%
Operating CF Growth %	-	-819.68%	-128.06%	-275.87%	120.4%	-25.82%	132.43%
Net Income	-1.64M	-29.18M	-375.11M	44.38M	-100.12M	-29.1M	-9.5M
Depreciation & Amortization	13.88M	14.4M	21.14M	22.02M	34.67M	33.68M	0
Stock-Based Compensation	103K	363K	12.42M	28.5M	22.54M	26.7M	0
Deferred Taxes	-4.65M	-4.34M	-3.76M	-1.79M	0	-3.75M	0
Other Non-Cash Items	1.94M	8.9M	335.62M	-59.42M	41.29M	16M	36.63M
Working Capital Changes	-7.91M	-2.58M	-18.66M	-140.28M	23.36M	-27.39M	10.37M
Change in Receivables	-11.05M	3.7M	-31.01M	-32.02M	12.85M	20.8M	8.59M
Change in Inventory	-4.77M	-3.21M	-9.44M	-82.1M	19.57M	-10.5M	15.8M
Change in Payables	4.31M	4.89M	10.52M	1.61M	15.78M	-43.78M	-7.2M
Cash from Investing	-12.48M	-3.82M	-37.73M	-18.87M	-31.51M	-6.79M	-5.16M
Capital Expenditures	-10.42M	-3.82M	-15.62M	-17.39M	-13.05M	-6.79M	-5.16M
CapEx % of Revenue	6.25%	3.21%	6%	4.75%	3.28%	2.03%	1.72%
Acquisitions	-2.06M	0	-22.9M	-1.48M	-18.46M	0	0
Investments	-	-	-	-	-	-	-
Other Investing	0	0	781K	0	0	0	0
Cash from Financing	14.58M	18.27M	959.03M	-205.24M	-37.45M	-158.34M	-174.9M
Debt Issued (Net)	16.5M	19.73M	524.51M	0	0	-156.08M	-173.35M
Equity Issued (Net)	0	-154K	938.38M	-160M	-35.63M	-1.96M	-1.57M
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	0	-154K	0	-160M	-32.4M	-1.96M	0
Other Financing	-1.92M	-1.3M	-503.86M	-45.24M	-1.82M	-302K	26K
Net Change in Cash	3.73M▲ 0%	2.18M▼ 41.6%	892.4M▲ 40854.6%	-333.69M▼ 137.4%	-45.17M▲ 86.5%	-152.96M▼ 238.6%	-137.4M▲ 10.2%
Free Cash Flow	-8.69M▲ 0%	-16.25M▼ 86.9%	-43.98M▼ 170.6%	-123.99M▼ 182.0%	8.7M▲ 107.0%	9.34M▲ 7.3%	37.18M▲ 298.1%
FCF Margin %	-5.22%	-13.65%	-16.91%	-33.89%	2.19%	2.79%	12.36%
FCF Growth %	-	-86.94%	-170.58%	-181.95%	107.02%	7.34%	298.09%
FCF per Share	-0.27	-0.47	-0.43	-0.83	0.07	0.07	0.27
FCF Conversion (FCF/Net Income)	-1.05x	0.43x	0.07x	-2.41x	-0.22x	-0.55x	-3.95x
Interest Paid	15.73M	13.54M	10.25M	0	9.38M	8.01M	0
Taxes Paid	861K	2.43M	1.7M	0	2.27M	2.8M	0

SKIN Key Ratios

The Beauty Health Company (SKIN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-	-	-278.16%	18.84%	-88.42%	-52.34%	-16.83%
Return on Invested Capital (ROIC)	5.56%	-7.18%	-18.49%	-7.79%	-30.72%	-18.88%	-6.83%
Gross Margin	63.92%	56.43%	68.65%	68%	38.97%	54.53%	65.29%
Net Margin	-0.98%	-24.5%	-145.63%	12.09%	-25.16%	-8.7%	-3.16%
Debt / Equity	-	-	2.47x	4.50x	12.67x	10.97x	6.20x
Interest Coverage	0.83x	-0.81x	-31.32x	4.39x	-6.46x	-1.84x	-1.08x
FCF Conversion	-1.05x	0.43x	0.07x	-2.41x	-0.22x	-0.55x	-3.95x
Revenue Growth	-	-28.53%	118.39%	40.67%	8.78%	-16%	-10.02%

SKIN SEC Filings & Documents

The Beauty Health Company (SKIN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 22, 2026·SEC

Material company update

Mar 12, 2026·SEC

Material company update

Mar 6, 2026·SEC

10-K Annual Reports

FY 2026

Mar 12, 2026·SEC

FY 2025

Mar 12, 2025·SEC

FY 2024

Mar 12, 2024·SEC

10-Q Quarterly Reports

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 7, 2025·SEC

FY 2025

May 8, 2025·SEC

SKIN Frequently Asked Questions

The Beauty Health Company (SKIN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

The Beauty Health Company (SKIN) reported $300.8M in revenue for fiscal year 2025. This represents a 81% increase from $166.6M in 2019.

The Beauty Health Company (SKIN) saw revenue decline by 10.0% over the past year.

The Beauty Health Company (SKIN) reported a net loss of $9.5M for fiscal year 2025.

Dividend & Returns

The Beauty Health Company (SKIN) has a return on equity (ROE) of -16.8%. Negative ROE indicates the company is unprofitable.

The Beauty Health Company (SKIN) generated $36.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More SKIN

The Beauty Health Company (SKIN) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→

The Beauty Health Company(SKIN)Earnings, Financials & Key Ratios

SKIN Key Insights

✓Strengths

✗Weaknesses

SKIN Price & Volume

SKIN Growth Metrics

Revenue CAGR

Profit CAGR

EPS CAGR

Return on Capital

SKIN Recent Earnings

SKIN Peer Comparison

Compare SKIN vs Peers

vs ELF

vs AMZN

Compare Top 5

SKIN Income Statement

SKIN Balance Sheet

SKIN Cash Flow Statement

SKIN Key Ratios

SKIN SEC Filings & Documents

8-K Announcements

10-K Annual Reports

10-Q Quarterly Reports

SKIN Frequently Asked Questions

Explore More SKIN

Total Return Calculator

DCA Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

Valuation